SCHEMBL23580992

SCHEMBL23580992

CC(C)(C)OC(=O)N1CC(O)C(C)(C(F)(F)F)C1

nearest known ligand 0.44

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
RORC P51449 13/20 0.41
NR1H2 P55055 1/20 0.41
USP2 O75604 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CHRM2 P08172 1/20 0.37
CHRM1 P11229 1/20 0.37
CHRM3 P20309 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17081079 0.82 NR1H2 (0.44) RORCNR1H2USP2SMN1; SMN2CHRM2
SCHEMBL22776027 0.82 NR1H2 (0.44) RORCNR1H2USP2SMN1; SMN2CHRM2
SCHEMBL17499914 0.82 NR1H2 (0.44) RORCNR1H2USP2SMN1; SMN2CHRM2
SCHEMBL30718602 0.81 NR1H2 (0.43) RORCNR1H2USP2SMN1; SMN2CHRM2
SCHEMBL16714648 0.81 NR1H2 (0.43) RORCNR1H2USP2SMN1; SMN2CHRM2
SCHEMBL17499855 0.81 NR1H2 (0.43) RORCNR1H2USP2SMN1; SMN2CHRM2
Methane SCHEMBL28623117 0.79 NR1H2 (0.42) RORCNR1H2USP2SMN1; SMN2CHRM2
SCHEMBL23608770 0.79 NR1H2 (0.39) RORCNR1H2USP2SMN1; SMN2CHRM2
SCHEMBL23608685 0.79 NR1H2 (0.39) RORCNR1H2USP2SMN1; SMN2CHRM2
SCHEMBL23580686 0.79 NR1H2 (0.39) RORCNR1H2USP2SMN1; SMN2CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114945571-B Cyclic compounds and methods of use thereof 薛定谔公司 2025-02-25 CN disclosed
CN-117999264-A Tricyclic compounds and methods of making the same 上海拓界生物医药科技有限公司 2024-05-07 CN disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 US disclosed
WO-2023051759-A1 TRICYCLIC COMPOUND AND PREPARATION METHOD THEREFOR 上海拓界生物医药科技有限公司 2023-04-06 WO disclosed
EP-4081526-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME Schrödinger, Inc. (US) 2022-11-02 EP disclosed
CN-114945571-A Cyclic compounds and methods of use thereof 薛定谔公司 2022-08-26 CN disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 WO disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME MALT1, FKBP1B, FKBP1A RORC 623/4885NR1H2 1989/4885USP2 2280/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.